UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended July 31, 1997
--------------------------------
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ______________ to _______________
Commission File Number 0-18724
----------------------------------------------
MARQUETTE MEDICAL SYSTEMS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Wisconsin 39-1046671
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification Number)
8200 W. Tower Avenue, Milwaukee, Wisconsin 53223
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(414) 355-5000
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
N/A
- --------------------------------------------------------------------------------
(Former Name, Former Address and Former Fiscal Year, if Changed Since
Last Report.)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days. Yes X No
----- -----
Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.
Outstanding
at August 31, 1997
-----------------------------
Common Stock, $.10 par value 17,684,953 Shares
-----------------------------
MARQUETTE MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
------------------------------------------------
INDEX
-----
Page Number
-----------
PART I - FINANCIAL INFORMATION:
- ------------------------------
Item 1) Financial Statements -
Consolidated Condensed Statements of Income 3
For the Three Months Ended July 31, 1997
and 1996 (Unaudited)
Consolidated Condensed Balance Sheets As of 4
July 31, 1997 (Unaudited) and April 30, 1997
Consolidated Condensed Statements of Cash Flows 5
For the Three Months Ended July 31, 1997
and 1996 (Unaudited)
Notes to Consolidated Condensed Financial 6
Statements (Unaudited)
Item 2) Management's Discussion and Analysis of Financial 7-9
Condition and Results of Operations
PART II - OTHER INFORMATION:
- ---------------------------
Item 4) Submission Of Matters To A Vote of Security Holders 10
Item 6) Exhibits and Reports on Form 8-K 10
SIGNATURE 11
- ---------
-2-
PART I - FINANCIAL INFORMATION
------------------------------
ITEM 1 - Financial Statements
- ------ --------------------
MARQUETTE MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF INCOME
(Amounts in Thousands, Except Per Share Data)
(UNAUDITED)
Three Months Ended
July 31,
---------------------
1997 1996
--------- ----------
Net Sales $132,069 $124,794
Cost of Sales 64,261 64,409
-------- --------
Gross profit 67,808 60,385
-------- --------
Engineering Expenses 12,725 11,794
Selling Expenses 34,191 31,373
General and Administrative
Expenses 11,708 10,578
-------- --------
Total operating expenses 58,624 53,745
-------- --------
Income from operations 9,184 6,640
Interest Expense 1,565 2,020
Other Income, Net (152) (601)
-------- --------
Income before provision for income
taxes 7,771 5,221
Provision for Income Taxes 3,470 1,951
-------- --------
Net Income $ 4,301 $ 3,270
======== ========
Net Income per Class A
Common Share $.24 $.20
======== ========
Shares used in per
share calculation 17,623 16,327
======== ========
The accompanying notes are an integral part of these statements.
-3-
MARQUETTE MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
(Amounts in Thousands, Except Per Share Data)
As of As of
ASSETS July 31, April 30,
- ------ 1997 1997
----------- ---------
CURRENT ASSETS: (Unaudited)
Cash and cash equivalents $ 4,797 $ 2,704
Accounts receivable, less allowances
of $4,237 and $4,164, respectively 139,698 140,136
Inventories 120,005 110,779
Prepaid expenses and other 5,306 4,850
Deferred income tax benefits 8,687 8,304
-------- --------
Total current assets 278,493 266,773
PROPERTY AND EQUIPMENT, NET 101,124 96,992
OTHER ASSETS 61,136 64,567
-------- --------
$440,753 $428,332
======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
- ------------------------------------
CURRENT LIABILITIES:
Amounts due to bank $ 9,196 $ 11,114
Notes payable to bank 42,458 30,422
Accounts payable 32,011 28,674
Accrued liabilities 48,332 47,381
-------- --------
Total current liabilities 131,997 117,591
-------- --------
LONG-TERM DEBT, less current maturities 52,500 57,000
DEFERRED INCOME TAXES 15,678 16,814
PENSION AND OTHER LONG-TERM LIABILITIES 45,724 45,727
CLASS A COMMON STOCK UNDER
REPURCHASE AGREEMENTS 8,000 8,000
SHAREHOLDERS' EQUITY:
Common Stock, $.10 par value,
30,000,000 shares authorized,
17,679,518 and 17,602,407 shares
issued, respectively 1,768 1,760
Additional paid-in capital 54,008 52,890
Retained earnings 151,644 147,343
Treasury stock, 316 and 18,900 shares,
at cost, respectively (5) (312)
Cumulative translation adjustment (12,561) (10,481)
Class A Common Stock under repurchase
agreements (8,000) (8,000)
-------- --------
Total shareholders' equity 186,854 183,200
-------- --------
$440,753 $428,332
======== ========
The accompanying notes are an integral part of these balance sheets.
-4-
MARQUETTE MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(Amounts in Thousands)
(UNAUDITED)
Three Months Ended
July 31,
------------------
1997 1996
-------- -------
CASH FLOWS FROM OPERATING ACTIVITIES $ 1,974 $(4,237)
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment additions, net (8,130) (6,152)
Net cash received from the sale of
Optical Devices, Inc. -- 905
------- -------
Net cash used in investing activities (8,130) (5,247)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable 11,327 14,192
to bank, net
Payments on long-term debt (4,500) (2,911)
Proceeds from issuance of common stock 1,432 47
------- -------
Net cash provided by financing
activities 8,259 11,328
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND
CASH EQUIVALENTS (10) (1,530)
------- -------
Net increase (decrease) in cash and
cash equivalents 2,093 314
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 2,704 2,890
------- -------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 4,797 $ 3,204
======= =======
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for-
Interest $ 1,596 $ 1,871
Income taxes $ 2,245 $ 807
The accompanying notes are an integral part of these statements.
- 5 -
MARQUETTE MEDICAL SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
AS OF JULY 31, 1997
(Amounts in Thousands, Except Per Share Data)
(UNAUDITED)
(1) Basis of Presentation-
Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to the rules and
regulations of the Securities and Exchange Commission. However, in the
opinion of the Company, adequate disclosures have been presented to make
the information not misleading, and all adjustments necessary to present
fair statements of the results of operations, financial position and cash
flows have been included. It is suggested that these consolidated condensed
financial statements be read in conjunction with the consolidated financial
statements included in Marquette Medical Systems, Inc.'s Form 10-K for the
fiscal year ended April 30, 1997.
(2) Inventories-
Inventories consist of the following:
July 31, 1997 April 30, 1997
------------- --------------
Raw materials and component parts $ 35,105 $ 31,629
Work in process and finished goods 60,755 56,434
Demonstration inventory 24,145 22,716
-------- --------
$120,005 $110,779
======== ========
-6-
ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
Results of Operations
RESULTS OF OPERATIONS - THREE-MONTH PERIOD ENDED JULY 31, 1997
Net sales for the three months ended July 31, 1997 increased $7.3 million, or
5.8 percent, to $132.1 million from $124.8 million for the three months ended
July 31, 1996. The Company's patient monitoring systems and diagnostic
cardiology product lines achieved sales growth of 15.5% and 0.4%, respectively
for the three-month period ended July 31, 1997 compared to the same period in
the previous fiscal year. The supplies and service product lines had a decrease
in net sales for the current quarter of 5.7% as compared to the previous year's
quarter.
The Company's patient monitoring systems product line continues to lead the
sales growth. The increased breadth and depth of the product line, especially
at the lower-price points, is generating the sales growth. The sales growth has
been led by the demand in the U.S. market. This demand has more than offset the
level of demand in the European markets which continue to be soft. In addition,
new distribution and marketing arrangements have enabled the Company to enter
additional markets.
The sales growth in the quarter was adversely affected by negative currency
conversions due to a stronger U. S. dollar. A stable U. S. dollar as compared
to the previous year's quarter would have provided additional net sales of $5.2
million, or 4.2%. The negative currency conversions and the weaker European
market have resulted in international net sales comprising 33.3% of the
Company's total net sales for the quarter as compared to 38.0% of net sales in
the previous year's quarter.
Gross profit for the three months ended July 31, 1997 increased 12.3% to $67.8
million from $60.4 million for the same period in the previous fiscal year.
Gross margin for the three-month period ended July 31, 1997 increased to 51.3%
from 48.4% for the same period in the previous fiscal year. The increase
relates to manufacturing efficiencies as well as the product mix which was
weighted towards higher margin products in the quarter. Offsetting the gross
margin increase to some extent were the continued pricing pressures in Europe.
Engineering expenses for the three-month period ended July 31, 1997 increased
7.9% to $12.7 million from $11.8 million for the same period in the previous
fiscal year. Engineering expenses as a percentage of net sales remained
relatively constant at 9.6% of net sales as compared to 9.5% of net sales for
the previous year's quarter. The Company will continue to invest significantly
in both new product developments and continued enhancements to current products.
Due to the competitiveness and technological nature of the medical systems and
equipment industry, this investment is necessary in order to maintain the
Company's competitive position in the health care industry.
Selling expenses for the three-month period ended July 31, 1997 increased 9.0%
to $34.2 million from $31.4 million for the same period in the previous fiscal
year. The increase relates primarily to the additional commissions earned as
the level of net sales and level of incoming orders have both increased. As a
percentage of net sales, selling expenses increased in the three-month period
ended July 31, 1997 to 25.9% of net sales from 25.1% of net sales in the
previous fiscal year.
- 7 -
General and administrative expenses for the three-month period ended July 31,
1997 increased 10.7% to $11.7 million from $10.6 million for the same period the
previous fiscal year. For the quarter, general and administrative expenses
increased as a percentage of net sales to 8.9% from 8.5% of net sales in the
previous fiscal year's quarter.
Operating income for the three-month period ended July 31, 1997 increased 38.3%
to $9.2 million from $6.6 million for the same period in the previous fiscal
year. The increased operating profit for the current fiscal year's quarter is
attributable to the sales growth and increased gross margins earned during the
quarter.
Interest expense for the three-month period ended July 31, 1997 decreased to
$1.6 million from $2.0 million for the same period in the previous fiscal year.
The decrease is attributable to the use of proceeds from a public stock offering
completed in March, 1997 for repayment of a portion of bank term debt.
The provision for income taxes for the three-month period ended July 31, 1997
was $3.5 million, or an effective tax rate of 44.7%, as compared to $2.0
million, or an effective tax rate of 37.4% for the same period in the previous
fiscal year. The increased effective tax rate is a result of the net operating
losses generated in some of the European operations during the quarter which
have not been benefited.
FINANCIAL OUTLOOK
In as much as the Company's principal product lines are all related to the
health care industry, they are subject to the current uncertainty surrounding
the industry including consolidation of hospital groups and a move towards
managed care. While the Company cannot predict the impact, if any, that such
modifications might have on its business, the Company's operating results are
closely linked to the health care economy. If revenue or earnings fail to meet
expectations of the investment community, there could be a significant impact of
the trading price of the Company's stock. Management believes that the
introduction of new products and the partnership relationships that have been
and continue to be established with the hospitals will keep the Company in a
competitive position as the health care economy demand for new equipment
increases.
LIQUIDITY AND CAPITAL RESOURCES
Working capital was $146.5 million at July 31, 1997 as compared to $149.2
million at April 30, 1997. Inventories increased by 8.3% to $120.0 million
primarily due to increased sales levels and to give the Company the continued
ability to effectively manage its backlog.
-8-
As of July 31, 1997, the Company had $15.6 million outstanding on U. S. lines of
credit of $25.0 million. In addition, the Company had $26.9 million, U. S.
dollar equivalent, outstanding on foreign lines of credit. As of April 30,
1997, the amounts outstanding on the U. S. and foreign lines of credit were $8.0
million and $22.4 million, respectively. A portion of the foreign currency
denominated borrowings are used to reduce the currency risks associated with
foreign currency receivables.
Capital expenditures for the three-month period ended July 31, 1997 were $8.1
million, compared with $6.2 million for the same period in the previous fiscal
year. The increase was due to the continued capital expenditures related to the
acquisition of a new business system. The capital purchases were funded by both
cash flow from operations as well as with draws from the working capital line.
The Company financed its $90.3 million fiscal 1996 acquisition of E for M
Corporation with three variable rate bank term loans each in the amount of $30.0
million. Each bank term loan is payable in eight equal semi-annual installments
of $3.75 million each beginning on April 30, 1997 and continuing on each October
31 and April 30 thereafter through October 31, 2000. During the fiscal year
ended April 30, 1997, the Company incurred $30.0 million of senior long-term
fixed-rate debt to refinance a portion of the bank term debt. This senior debt
accrues interest at a fixed rate of 7.46% per annum and matures on August 29,
2008. As of April 30, 1997, the Company had repaid or refinanced $63.0 million
of such bank term debt. In the three-month period ended July 31, 1997, the
Company repaid an additional $4.5 million of the bank term debt with draws from
the working capital line. The next required installment owed by the Company is
April 30, 2000. The $22.5 million of remaining bank term debt outstanding on
July 31, 1997 accrued interest at a rate equal to the LIBOR rate plus one
percent, reset monthly. At July 31, 1997, the rate was 6.625% per annum. The
Company intends to pay the interest and retire the remaining long-term debt
through cash flow from operations.
Management believes the Company has the financial resources to meet its short
term and long term cash requirements. Management believes its cash flow from
operations will be sufficient to continue to fund its current obligations as
well as fund the internal growth of the Company. The current U.S. inflation
rate has little impact on Company operations.
The Management Discussion and Analysis of Financial Conditions and Results of
Operations section in this report may contain certain forward-looking statements
regarding the Company and its products. These forward-looking statements are
based on current expectations and the Company assumes no obligation to update
this information. The Company's actual results could differ materially from
those discussed in this document.
-9-
PART II - OTHER INFORMATION
ITEM 4 - Submission of Matters To A Vote of Security Holders
(a) On Wednesday, August 13, 1997 at 9:00 a.m. the Annual
Meeting of Shareholders of Marquette Medical Systems, Inc.
was held at the Company's offices, 8200 West Tower Avenue,
Milwaukee, Wisconsin 53223.
(b) Six Directors were elected at the meeting to serve until the
next Annual Meeting of Shareholders and until their
successors are elected and qualified. The elected Directors
are Timothy C. Mickelson, Michael J. Cudahy, Frederick G.
Luber, Melvin S. Newman, Walter L. Robb and John G.
Bollinger.
(c) The shareholders ratified the selection of Arthur Andersen
LLP as the Company's independent public accountants for the
year ending April 30, 1998.
(d) The shareholders approved the amendment of the Registrant's
Amended and Restated Articles of Incorporation to eliminate
the Class C Common Shares as an authorized class of stock
and to rename the Class A Common Shares to Common Shares.
ITEM 6 - Exhibits and Reports on Form 8-K
A report on Form 8-K was filed on June 24, 1997 related to the
issuance of a stock option to Michael J. Cudahy, the Chief Executive
Officer and director of the registrant.
-10-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Marquette Medical Systems, Inc.
----------------------------------
(Registrant)
Date: 9-11-97 /s/ Mary M. Kabacinski
--------------------- -------------------------------
Mary M. Kabacinski
Principal Financial Officer
and Duly Authorized Officer
- 11 -